Paediatric low-grade glioma: the decisions you may face

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

1. Is MRI the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
   Why: A single standard does not mean a single choice; timing and trials are decisions too.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. Does your recommendation follow the current guideline (NCI PDQ: childhood astrocytomas, other gliomas and glioneuronal tumours), and if it departs from it, why?
   Why: Departures from guidelines are sometimes right for an individual; they should be explained.
5. For my situation (resectable tumour), which of the standard options do you recommend and why?
   Why: Guideline options include: Maximal safe resection; gross total resection is curative in most and no adjuvant therapy is given. Observation for stable residual disease.

Add these to your appointment list, or take the full question set for this cancer.

• TADPOLE (CDRB436G2201)Phase 2NCT026840582023110 peopleevidence 63
  Tests Dabrafenib + trametinib
  Newly diagnosed BRAF V600-mutant paediatric low-grade glioma needing systemic therapy: dabrafenib + trametinib vs carboplatin + vincristine (2:1 randomisation)

  ORR 47% vs 11%; median PFS 20.1 vs 7.4 months, HR 0.31.

  Overall response rate (independent review, RANO) (%): Dabrafenib + trametinib 47 (n=73) vs Carboplatin + vincristine 11 (n=37) · source

1. Is Dabrafenib + trametinib the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
   Why: A single standard does not mean a single choice; timing and trials are decisions too.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. How closely do I match the people in TADPOLE (CDRB436G2201), and does that change what the results mean for me?
   Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
4. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
5. Does your recommendation follow the current guideline (FDA label 2023; NCI PDQ), and if it departs from it, why?
   Why: Departures from guidelines are sometimes right for an individual; they should be explained.
6. For my situation (unresectable or progressive, braf v600e), which of the standard options do you recommend and why?
   Why: Guideline options include: Dabrafenib plus trametinib first line (TADPOLE: higher response rate and longer progression-free survival than carboplatin-vincristine; FDA approval March 2023 for patients aged one year and over).
7. Am I a candidate for Dabrafenib + trametinib, and what side effects should I expect?
   Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
8. How do the results of TADPOLE (CDRB436G2201) apply to someone like me?
   Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

• FIREFLY-1Phase 2NCT047754852023141 peopleevidence 54
  Tests Tovorafenib
  Relapsed or refractory BRAF-altered paediatric low-grade glioma: single-arm tovorafenib (arm 1, n = 77 registrational cohort)

  ORR 67% (RANO-HGG) and 51% (RAPNO-LGG) in arm 1; median DOR 16.6 months.

  Overall response rate (RANO-HGG, independent review) (%): Tovorafenib (arm 1) 67 (n=77) · source

No side-effect rates or interaction flags are recorded for these options yet. The side-effect lookup and interaction checker cover the products that have them.

1. Is Tovorafenib the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
   Why: A single standard does not mean a single choice; timing and trials are decisions too.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. How closely do I match the people in FIREFLY-1, and does that change what the results mean for me?
   Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
4. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
5. Does your recommendation follow the current guideline (FDA accelerated approval 2024), and if it departs from it, why?
   Why: Departures from guidelines are sometimes right for an individual; they should be explained.
6. For my situation (relapsed or refractory, braf fusion or v600e), which of the standard options do you recommend and why?
   Why: Guideline options include: Tovorafenib (FIREFLY-1; FDA accelerated approval April 2024 for patients aged six months and over), or a MEK inhibitor such as selumetinib in trials.
7. Am I a candidate for Tovorafenib, and what side effects should I expect?
   Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
8. How do the results of FIREFLY-1 apply to someone like me?
   Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

1. Between Carboplatin, Vincristine, Vinblastine and the other options, which do you recommend for me, and what about my case would make you choose differently?
   Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
   Why: The aim shapes how much side effect and disruption is worth accepting.
3. What happens if I delay, or decline this step for now? Is the decision reversible?
   Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
4. Does your recommendation follow the current guideline (NCI PDQ; SIOPE LGG guidance), and if it departs from it, why?
   Why: Departures from guidelines are sometimes right for an individual; they should be explained.
5. For my situation (unresectable, no targetable alteration or targeted drug unavailable), which of the standard options do you recommend and why?
   Why: Guideline options include: Carboplatin and vincristine, or weekly vinblastine, to defer radiotherapy; focal conformal or proton radiotherapy is reserved for older children and for progression after systemic options.
6. Am I a candidate for Carboplatin, Vincristine, Vinblastine, and what side effects should I expect?
   Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.